Brivaracetam is indicated towards treatment of epilepsy.
Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact®.
The Company affirmed that NATCO’s BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively.
Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.
At around 12:30 PM, Natco Pharma was trading at Rs803.35 per piece up by Rs1.65 or 0.21% on the BSE.